UM-HMC-3B cells

Unit

3 x 10^6 cells/ml

Cell Type

Tumor Cells

Tissue Type

Head-Neck cancer cell lines

Organism

Human

Donor History

Hard palate mucoepidermoid carcinoma

Growth Properties

Adherent

Growth Conditions

Culture medium: DMEM:Ham's F12 (1:1)

,

w: 3.1 g/L Glucose

,

w: 2.5 mM L-Glutamine

,

w: 15 mM HEPES

,

w: 0.5 mM Sodium pyruvate

,

w: 1.2 g/L NaHCO3 (Cytion article number 820400a). Supplements: Supplement the medium with 10% FBS. Dissociation reagent: Accutase. Seeding density: 2-4*10^4/cm². Freeze medium: As a cryopreservation medium

,

we use complete growth medium (including FBS) + 10% DMSO for adequate post-thaw viability

,

or CM-1 (Cytion catalog number 800100)

,

which includes optimized osmoprotectants and metabolic stabilizers to enhance recovery and reduce cryo-induced stress. Incubation atmosphere: 37°C

,

5% CO2

,

humidified atmosphere.

Immortalization Method
Full Information

https://www.cytion.com/UM-HMC-3B-cells/305715

SKU: 305715 Kategorie: ,
Mgr. Otakar Fišer
Máte otázky k tomuto produktu? Kontaktujte našeho specialistu.
Mgr. Otakar Fišer
Produktový manažer - Life Science
Popis

UM-HMC-3B is a human mucoepidermoid carcinoma cell line established from a primary mucoepidermoid carcinoma of the hard palate salivary glands of a 73-year-old Caucasian female patient. The line is is part of the University of Michigan Human Mucoepidermoid Carcinoma (UM-HMC) panel. Like UM-HMC-1, UM-HMC-3B harbors the CRTC1-MAML2 gene fusion (MECT1-MAML2), the oncogenic driver in the majority of mucoepidermoid carcinomas, which results from a t(11;19)(q21;p13) translocation and drives CREB and Notch pathway activation.
UM-HMC-3B is applicable in studies of hard palate and salivary gland mucoepidermoid carcinoma biology, CRTC1-MAML2 signalling, and comparative analyses with other UM-HMC panel lines. Together with UM-HMC-1 and other panel members, UM-HMC-3B enables identification of common and divergent molecular features across mucoepidermoid carcinomas of different anatomical sites, ages, and genders. It is also suitable for drug sensitivity assays targeting fusion oncoproteins and downstream CREB/Notch effectors.

O značce

Společnost Cytion vznikla v roce 2004 v německém Heidelbergu s jasným vědeckým posláním: dodávat ověřené lidské a zvířecí buněčné linie bez kontaminace, připravené za přísně kontrolovaných laboratorních podmínek.

Postupně se vypracovala ve spolehlivou buněčnou banku, která slouží akademickým laboratořím, biotechnologickým firmám i farmaceutickým výzkumným týmům po celém světě. Klade přitom důraz na reprodukovatelnost výsledků, přísnou kontrolu kvality a dlouhodobá partnerství.